Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA (2016 - 2025)

Historic EBITDA for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$34.3 million.

  • Viridian Therapeutics, Inc.\DE's EBITDA rose 5439.01% to -$34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 1813.91%. This contributed to the annual value of -$270.3 million for FY2024, which is 1404.65% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's EBITDA stood at -$34.3 million, which was up 5439.01% from -$100.9 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBITDA peaked at -$14.0 million during Q3 2021, and registered a low of -$100.9 million during Q2 2025.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's EBITDA averaged around -$49.4 million, with its median value being -$47.6 million (2023).
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's EBITDA in the last 5 years was 6793.39% (2021), contrasted with its biggest fall of 17902.1% (2021).
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's EBITDA (Quarter) stood at -$29.1 million in 2021, then plummeted by 55.45% to -$45.2 million in 2022, then tumbled by 46.92% to -$66.5 million in 2023, then decreased by 21.38% to -$80.7 million in 2024, then soared by 57.47% to -$34.3 million in 2025.
  • Its EBITDA was -$34.3 million in Q3 2025, compared to -$100.9 million in Q2 2025 and -$86.7 million in Q1 2025.